Sandhoff disease is a severe inherited neurodegenerative disorder resulting from deficiency of the b-subunit of hexosaminidases A and B, lysosomal hydrolases involved in the degradation of G M2 ganglioside and related metabolites. Currently, there is no viable treatment for the disease. Here, we show that adenovirus-mediated transfer of the bsubunit of b-hexosaminidase restored Hex A and Hex B activity after infection of Sandhoff fibroblasts. Gene transfer following intracerebral injection in a murine model of Sandhoff disease resulted in near-normal level of enzymatic activity in the entire brain at the different doses tested. The addition of hyperosmotic concentrations of mannitol to the adenoviral vector resulted in an enhancement of vector diffusion in the injected hemisphere. Adenoviral-induced lesions were found in brains injected with a high dose of the vector, but were not detected in brains injected with 100-fold lower doses, even in the presence of mannitol. Our data underline the advantage of the adjunction of mannitol to low doses of the adenoviral vector, allowing a high and diffuse transduction efficiency without viral cytotoxicity.
Introduction
Sandhoff disease is an autosomal recessive lysosomal storage disorder due to mutations in HEXB, the gene coding for the b-subunit of b-hexosaminidases A and B (Hex A and Hex B; structure ab and bb, respectively). Like Tay-Sachs disease, which is caused by mutations in the HEXA gene encoding the a-subunit, Sandhoff disease is a G M2 gangliosidosis, a disorder characterized by profound lysosomal accumulation of G M2 ganglioside, especially in the nervous system. Both Hex A and Hex B activities are deficient in Sandhoff disease, whereas only the Hex A isoenzyme is affected in Tay-Sachs disease. Both disorders exhibit similar clinical pictures. In the infantile form (the most common), onset of the disease occurs at 3-6 months of age and follows a rapidly neurodegenerative course, culminating in death before 4 years of age. Later-onset forms, caused by mutations with milder impact, progress more slowly and display a large spectrum of neurologic manifestations. 1 The inability to treat the G M2 gangliosidoses has stimulated interest in the development of specific animal models, to enable experimentation with different approaches to therapy. To this end, we have constructed a mouse model of Sandhoff disease, by disruption of the murine Hexb gene, 2, 3 in order to enable gene transfer experiments. Affected Hexb À/À mice display profound neurologic involvement and massive storage of G M2 ganglioside throughout the brain and spinal cord beginning at about 3 months with death 4-6 weeks later.
A major challenge to the treatment of central nervous system (CNS) diseases using gene therapy is to overcome access to the brain and to transduce a neuronal cell population that no longer undergoes cell division. Replication-defective adenoviral (Ad) vectors efficiently infect postmitotic cells, including neurons and glial cells. [4] [5] [6] [7] Such vectors have already been tested for lysosomal storage diseases affecting the CNS. [8] [9] [10] We previously used Ad-mediated gene transfer to restore Hex A activity in fibroblasts from patients with TaySachs disease and in vivo in the Hexa À/À knockout mouse. 11, 12 In this study, we tested the feasibility of HEXB gene transfer into the CNS of the Hexb À/À mouse model. A limitation in the use of many viral vectors is poor diffusion and a low level of retrograde transport, which restrict gene transfer to the area of the injection site in the CNS. 4 One solution to this problem may be to introduce the vector in a hyperosmotic solvent, as recently demonstrated for AAV transduction by Mastakov et al. 13 We now demonstrate that Ad-mediated transfer of the HEXB gene in the CNS was enhanced by the adjunction of mannitol to the transfer solution.
Results
Restoration of X -hexosaminidase activity after infection of Sandhoff fibroblasts with recombinant vector
Fibroblasts deficient in the b-subunit of b-hexosaminidase were incubated with increasing concentrations of Ad.HEXB and b-hexosaminidase activity was assayed 2 days postinfection. MUG hydrolysis, measuring Hex A þ Hex B activities, increased with viral titer until it reached twice the normal level of activity, while MUGS hydrolysis (Hex A specific) approached the normal level of enzyme activity at the highest viral titer used (Table 1) . In parallel, Sandhoff cells incubated with the same concentrations of Ad.lacZ showed background levels of Hex A and Hex B activities (not shown). Corrected cells secreted b-hexosaminidase into the culture medium at the same level as normal fibroblasts. This experiment demonstrated the efficacy of the Ad.HEXB viral construct and showed that the expressed b-subunit could contribute to both Hex A and Hex B activities.
In situ b-hexosaminidase activity was assayed on fibroblasts infected with Ad.HEXB using the naphthol AS-BI derivative of N-acetyl-b-D-glucosaminide as a substrate. A bright-red staining was obtained on infected cells (Figure 1c and d) , showing restoration of b-hexosaminidase activity. This result compared favorably with that obtained with normal cells, which showed a homogeneous but less intense staining ( Figure  1a ) and contrasted markedly with uninfected deficient cells, which exhibited a complete lack of dye product ( Figure 1b ).
X -Hexosaminidase activity in mouse brains injected with Ad.HEXB b-Hexosaminidase cleavage of MUG and MUGS was evaluated in brain extracts from mice injected with varying doses of Ad.HEXB7mannitol 13 days postinjection. Brains were cut into four pieces and assayed separately. For Hexb þ / þ and noninjected Hexb À/À mice, the two hemispheres were pooled.
In Hexb À/À mice injected with Ad.HEXB, Hex A þ B activity was greater than the level of control Hexb þ / þ mice ( Table 2 ). This occurred not only in the injected hemisphere, but also in the contralateral hemisphere and in the brain stem and cerebellum. This increase was most dramatic in Hexb À/À mice injected with the highest dose of vector. The level of activity was similar to cohorts injected with or without the addition of mannitol. Interestingly, we also observed a slight increase in the Hex A activity with 4 Â 10 8 ip of Ad.HEXB, in comparison with untreated or Ad.lacZ injected (not shown) Hexb À/À mice.
X -Hexosaminidase isoenzymes pattern in the same injected mice DEAE-cellulose chromatography was used to separate the b-hexosaminidase isoenzymes in brain extracts obtained from Hexb À/À mice treated with 4 Â 10 8 ip of Ad.HEXB. Elution patterns were compared with those obtained under the same chromatographic conditions for brain extracts from normal and Sandhoff mice. Eluates were assayed for MUG versus MUGS hydrolysis to assign the isoenzyme peaks. As shown in Figure 2a , b-hexosaminidase from normal brain extract resolved in three peaks of activity, eluting in positions corresponding to Hex B (bb structure, as revealed by its inability to hydrolyze the MUGS substrate), a Hex intermediate form which displays a Hex B-like structure 14 and Hex A (ab), respectively. In the brain extract from a Hexb À/À mouse (Figure 2b ), only the Hex S isoenzyme (aa structure) was detected, eluting within the NaCl gradient just after the elution point of Hex A. 15 Treatment of Hexb À/À mice with Ad.HEXB resulted in the appearance of Hex B and Hex A isoforms in both the injected and contralateral hemispheres (Figure 2c and d, respectively) . The restoration of Hex B activity reached a very high level, but the increase in Hex A was much weaker.
Enzyme distribution in the brain parenchyma
A specific enzymatic staining using a synthetic bhexosaminidase substrate coupled to a naphthol residue was performed on brain cryosections. In the mice injected with Ad.HEXB alone, b-hexosaminidase-positive cells were restricted primarily to the region surrounding the needle track (Figure 3c, g ). Positive cells were also present in the ventricular region of the hemispheres and of the cerebellum: most of them were located in the choroid plexus and the ependymal wall of the ventricles (Figure 3g ). Some positive cells were also present in the striatum, at further distances from the needle track, and in the cortex.
After coinjection of Ad.HEXB with mannitol, the extent of hexosaminidase staining significantly increased. The stained area was similar in mice injected with the lowest (4 Â 10 6 ip) or the highest (4 Â 10 8 ip) dose. The whole striatum, the internal and external Adenoviral gene therapy of Sandhoff disease C Bourgoin et al capsules and the thalamus showed an intense red dye, indicative of b-hexosaminidase activity (Figure 3a , e). A large diffusion was observed from the highly transduced external capsule to the hippocampus. Numerous positive cells were also present throughout the cortex, including the periphery of blood vessels and the region surrounding the hippocampal fissure.
Histochemical analysis of tissue damage caused by the injections
In order to determine whether mannitol and/or adenoviral vector injections produced tissue damage, Hexb
mice were injected with Ad.lacZ at different doses7 mannitol, with mannitol alone or with NaCl. Short-term (2 days) or delayed (13 days) lesions were analyzed using Luxol-fast blue staining of sagittal brain sections around the injection point ( Figure 4 ). Their rostro-caudal diffusion is summarized in Figure 5 .
In the mice injected with the highest dose, several kinds of lesions were found in the vicinity of the injection site such as cellular debris and spongiosis, as well as hypercellularity and severe demyelination (Figure 4d ). Other lesions were seen at some distance from the injection point: intraparenchymal and perivascular cuffing in various regions of the brain (Figure 4d , right box) and microglial reaction in the basal ganglia. No significant lesions were found in the cortex and hippocampus, except along the needle track.
Cellular debris, consisting of nuclear fragments derived from cellular necrosis, were the earliest visible lesions, observed 2 days after injection (data not shown). Cuffing and microglia activation, reflecting inflammatory response, as well as spongiosis, were intermediate lesions found at 2 and 13 days postinjection. Severe demyelination and reactive hypercellularity were delayed lesions found 13 days postinjection.
Spongiosis was observed even in mice injected with mannitol alone or with NaCl, but it had a perilesional and very focal location ( Figure 5 ). In the presence of Ad.lacZ, spongiosis was detected along the myelinated fiber tracts (corpus callosum and internal capsule) and it progressed to cavitation when mannitol was added to Ad.lacZ (Figure 4d , left box). Local hypercellularity was also found after mannitol or NaCl injection, but the intensity and spread of the phenomenon increased with Ad.lacZ and diffused still more after coadministration with mannitol ( Figure 5 ). Some lesions such as cellular debris, microglial activation and cuffing were specific for Ad.lacZ. Mannitol increased the intensity of these lesions, but not their diffusion ( Figure 5 ). Ad vector also induced specific demyelination. The diffusion of this lesion increased with mannitol, reaching the striatum, the internal capsule and the thalamus (Figure 4d ).
Brain lesions were also analyzed in correlation with the dose of adenoviral vector. In comparison with the results obtained above with the highest dose, mice injected with 4 Â 10 6 and 4 Â 10 7 ip showed fewer and less diffuse lesions ( Figure 5 ). Although adenoviralspecific lesions were detected in mice receiving 4 Â 10 7 ip of the vector, they were restricted to the vicinity of the injection site, even after the addition of mannitol. These lesions were not observed in mice injected with 4 Â 10 6 ip (Figure 4b ).
Discussion
A single vector injection leading to a complete restoration of b-hexosaminidase activity In the present study, an adenoviral vector encoding the b-hexosaminidase b-subunit was injected into the CNS of Hexb À/À mice. A single injection of the vector at different doses led to at least a normal level of b-hexosaminidase activity in the injected hemisphere and also in the contralateral hemisphere, the cerebellum and the brain stem.
The distribution of transduced cells within the contralateral hemisphere suggests that the majority of positive cells were restricted to the ventricular area. This Despite the global restoration of enzyme activity, it is likely that the diffusion of the enzyme from the injection area and from the ventricles may not be sufficient to correct the entire brain parenchyma. Consequently, alternative strategies should be considered such as (I) multiple injections in different regions of the brain, (II) the use of methods to increase the diffusion efficiency into the parenchyma, (III) or the use of a vector that is readily transported to afferent regions by axonal retrograde transport. 16 Mannitol enhanced enzyme distribution in the injected hemisphere of Hexb À/À micey
We examined the potential for enhanced delivery through the inclusion of mannitol in the injection solution. Hyperosmotic concentrations of mannitol have often been used to disrupt the blood-brain barrier after intra-arterial injections. [17] [18] [19] In a different strategy, intracerebral coadministration of mannitol with gene transfer vectors has been described to generate an enhancement of gene delivery into the rat brain. 13 The benefit of mannitol can be explained as a local osmotic effect accompanied by a shrinkage of the cells and an enlargement of the interstitial space, facilitating the diffusion of the vector. Thus, mannitol allowed a much higher diffusion of the vector in the brain parenchyma, ensuring correction throughout the injected hemisphere, even at the weakest dose. A particular benefit of mannitol is that it might allow for a dramatic, but transient diffusion of injected vector. As such, the use of mannitol in the injection solution could reduce the number of injections necessary to permit complete correction of the CNS. In our study, in the absence of mannitol, most of the positive cells were located along the needle track. In contrast, mice coinjected with Ad.HEXB and mannitol showed a significant increase in enzyme distribution with positive histochemical staining across a large region of the brain parenchyma. While there was a large increase in the number of transduced cells, each of them might have been transduced by less viral particles, resulting in nearly similar enzyme activities in the overall homogenates. 4 Under certain pathophysiological conditions, the correction of all the cells in an affected organ is not necessary. This may be particularly true for lysosomal Adenoviral gene therapy of Sandhoff disease C Bourgoin et al storage diseases. Indeed, in the normal biosynthetic pathway, many of these enzymes are partitioned between lysosomal targeting and secretion. In some cases, the secreted enzyme can be taken up by distant cells and delivered to the lysosome, using the mannose-6-phosphate receptor pathway. 20 Ganglioside hydrolases are not readily taken up by other cells, but cells that overexpress these enzymes, such as transduced cells, may secrete the enzyme in high uptake form. 11, 12 In our study, enzymatic assays on transduced cell supernatants confirmed efficient secretion of the enzyme. Moreover, specific enzymatic staining of brain cryosections revealed cells with intense intracellular staining, and also cells with diffuse precipitates likely corresponding to internalized enzyme. Further studies will be necessary to confirm whether the internalized enzyme is targeted to lysosomes, as expected. This secreting capacity, associated to the widespread transduction of cells by the vector when hyperosmotic mannitol is included in the injection solution, might amplify the potential for correction after adenoviral vector injection in our model.
yAnd did not induce any specific brain lesion
A key issue for the injection of viral vectors is their potential for toxicity. First generation human Ad vectors tend to induce lesions in the mammalian brain, due to their inflammatory and cytotoxic properties. 21, 22 We investigated whether any structural damage was associated with the use of the Ad vector, mannitol or the injection procedure. The highest dose of Ad vector induced short-term cellular destruction, microglial activation, 23 cuffing and severe demyelination of the transduced area. Mannitol increased these lesions likely due to enhanced diffusion of the vector and more 
Adenoviral gene therapy of Sandhoff disease
C Bourgoin et al widespread vector-induced toxic effects. It led mainly to an enhancement of the extent of delayed lesions such as demyelination and hypercellularity and of damage associated with cellular debris, spongiosis, cuffing and microglial reaction. However, mannitol did not induce specific lesions. Significantly, the use of mannitol permitted a decrease in the vector dose, which resulted in less intense cytotoxicity and immune reaction, and efficient gene expression. Various methods have been developed in order to decrease the toxicity of CNS gene delivery, such as immunosuppression of the animals. 24 Potentially less pathogenic vectors are also being investigated, including 'gutless' adenoviral vectors, 25 canine adenovirus vectors (CAV-2), 16 AAV, 26 and lentiviral vectors. 27 Such vectors will also have to be designed for Sandhoff disease gene therapy and their use compared to adenoviral vectors in terms of transduction efficiency, vector diffusion and potential deleterious effects. However, AAV and HIV vectors are integrative (even if it is still controversial for AAV vectors), 28, 29 and this capacity is not necessary for long-term expression in postmitotic cells, such as neural cells. Thus, adenoviral vectors are attractive gene transfer tools for diseases affecting the CNS, as their DNA remains episomal and therefore cannot induce any insertional mutagenesis.
This study did not specifically address the therapeutic impact of Ad.HEXB-mediated therapy. The restoration of G M2 ganglioside catabolism would require the synthesis and lysosomal targeting of Hex A. Most of the isoform synthesized as a result of the vector injection was the bb homodimer (Hex B). Hex A was also generated, although to a lesser extent, demonstrating that recombinant bsubunit associated with endogenous a-subunit to form Hex A. It is of importance to note that while Hex B can degrade glycolipids such as G A2 and globoside, only Hex A can catabolize G M2 ganglioside, the major component that accumulates in Sandhoff disease. We previously showed that overexpression of both a-and b-subunits was necessary to obtain therapeutic levels of Hex A in a mouse model of Tay-Sachs disease. 12 It is likely that the same approach, requiring transduction of genes for both the a-and b-subunits, will be required for effective correction in the Sandhoff disease model. In summary, our results strongly argue for the use of mannitol in combination with low doses of adenoviral vectors, allowing a high efficiency of expression and a wide diffusion without a significant deleterious effect. This strategy could be relevant for neurological diseases with diffuse, systemic involvement, such as lysosomal storage diseases, especially when addressing larger animal models or, ultimately, patients.
Materials and Methods
Generation of an adenoviral vector recombinant for the b-subunit of hexosaminidases (Ad.HEXB)
The human HEXB cDNA (a generous gift from Dr Don Mahuran, Toronto, Canada) was isolated from a pBluescript plasmid (pBsIISK-bHex) generating a 1814-pb fragment. It was then ligated into the adenoviral plasmid described in Kremer and Perricaudet 30 to generate an E1, E3-deleted Ad-vector (Ad.HEXB) using standard molecular biology techniques. The viral titer obtained was 1.2 Â 10 12 ip/ml. Ip were determined using the Replication Center Assay (RCA). Ad.lacZ encodes nuclear targeted Escherichia coli b-galactosidase. Its titer was: 9 Â 10 10 ip/ml. HEXB and lacZ expression is driven by the cytomegalovirus early region promoter (CMV). 31 
Infection of Sandhoff fibroblasts with the recombinant adenovirus
Human cultured fibroblasts (GM00317A) were obtained from Coriell Cell Repositories (Camden, NJ, USA). They were plated at a density of 4 Â 10 5 cells per 25 cm 2 dish in Dulbecco's modified Eagle medium (DMEM) with 10% fetal calf serum. Cells were infected with different titers of viral suspension (100 and 1000 ip/cell) diluted in 500 ml culture medium without serum and incubated at 371C for 90 min. The medium was then brought to 5 ml with the addition of DMEM with serum and the plates were incubated at 371C for 24 h. The medium was then replaced and cells were maintained at 371C for an additional 24 h.
In vivo Ad.HEXB administration in Hexb
À/À mice
The Hexb À/À mouse model used in this study has been described previously.
2 One-month-old Hexb À/À mice were anesthetized with ketamine/xylazine (80 mg/ 4 mg/kg) and placed in a stereotaxic apparatus (David Kopf, Tujunga, CA, USA). Intracerebral injections were performed with the following coordinates: AP -1.5 mm, ML þ 2 mm, DV -3 mm. 32 In a total volume of 3 ml, 4 Â 10 6 , 4 Â 10 7 , or 4 Â 10 8 ip were injected at a rate of 0.5 ml/min using a 10 ml Hamilton syringe and a microprocessor-controlled micropump (KD Scientific, Boston, MA, USA). For each dose, eight mice received 2.2 ml of Ad.HEXB 70.8 ml of 20% mannitol (Maco Pharma, Utrecht, The Netherlands). Ad.lacZ was injected using the same conditions. The mice were killed under deep anesthesia 13 days postinjection. For biochemical analysis, brains were divided into four pieces: right (injected) and left (noninjected) hemispheres, cerebellum and brain stem, and immediately frozen on dry ice. For histochemical analysis, the entire brain was directly frozen. 10 mm cryosections were produced using a cryostat apparatus (Leica, Nussloch, Germany). Slides were kept frozen at À801C before analysis.
b-hexosaminidase activity assay Cell and tissue extraction. Cells were collected by scraping and centrifuged at 2500 rpm. Cell pellets were resuspended in water and frozen and thawed three times.
Brain samples were homogenized in 10 mM sodium phosphate buffer, pH 6.0, containing 0.1% (v/v) Nonidet NP40 (Sigma, St Louis, MO, USA). The homogenates were centrifuged at 12000 rpm in an Eppendorf microfuge for 20 min and supernatants were used as tissue extracts for enzyme analysis. All procedures were carried out at 41C.
Enzyme assays. Enzyme activities of cell or tissue extracts were determined using the 4-methylumbelliferyl derivatives of either -N-acetylglucosaminide (MUG) or -N-acetylglucosamine-6-sulfate (MUGS) (Sigma, St Louis, MO, USA) as previously described. 33 The MUG Adenoviral gene therapy of Sandhoff disease C Bourgoin et al substrate is used for the determination of total bhexosaminidase (Hex A þ Hex B), while the MUGS substrate is specific to Hex A. Protein was determined using the Bio-Rad protein assay system (Bio-Rad Laboratories, Hercules, CA, USA).
-Hexosaminidase isoenzyme analysis. Brain extracts were analyzed by ion-exchange chromatography on DE-52 DEAE-cellulose (Whatmann Biochemicals, UK). 15 The chromatography was performed using 1 ml column equilibrated with 10 mM sodium phosphate buffer, pH 6.0. Proteins retained by the column were eluted using a linear gradient of NaCl (0.0-0.3 M in 30 ml of the above buffer). Finally, the proteins were eluted with 1.0 M NaCl in the same buffer. The flow rate was 0.5 ml/min. Fractions (1 ml) were collected and assayed for b-hexosaminidase activity. On Hexb À/À mice tissues. Cryosections were fixed in a solution containing 2% formaldehyde, 0.2% glutaraldehyde and 0.01% Nonidet P40 for 15 min at þ 41C. After subsequent washes in C/P buffer (0.1 mM citrate, 0.2 mM phosphate, pH 4.5), slides were incubated with 0.3 g/l naphthol AS-BI N-acetyl b-D glucosaminide, 1 g/l fast garnet GBC salt in C/P buffer for 1 h at room temperature. After a wash in sterile water, slides were mounted in an aqueous Aquamount solution (BDH, Poole, UK).
In vivo Ad.lacZ. administration in Hexb þ / þ mice For lesions analysis, mice were injected with a 3 ml solution containing 4 Â 10 6 , 4Â 10 7 or 4 Â 10 8 ip of Ad.lacZ. For each dose, a cohort of mice (n¼6) received Ad.lacZ alone and another Ad.lacZ together with 0.8 ml of 20% mannitol. Other cohorts of mice were injected in the same final volume, either with 0.8 ml of 20% mannitol (n¼4) or with 0.9% NaCl (n¼4). For each cohort, half the mice were killed 2 days postinjection for short-term tissue damage analysis and the remaining mice were killed 13 days postinjection.
Histological analysis
Tissues were fixed by intracardiac perfusion of 20 ml PBS (Invitrogen, Carlsbad, CA, USA) and 20 ml of 4% PFA in PBS, after deep anesthesia. Brains were kept overnight in 4% PFA and processed for paraffin embedding. For each brain, 10 mm sections were produced at every 1 mm and stained either with hematoxylin-eosin and cresyl violet for tissue morphology or with Luxol-fast blue for myelin analysis.
